A retrospective study of initial dose of sorafenib therapy in Japanese patients with unresectable hepatocellular carcinoma -experiences from a single center

Takeda Haruhiko, Osaki Yukio, Ohara Yoshiaki, Sakamoto Azusa, Saito Sumio, Nishijima Norihiro, Nasu Akihiro, Nishikawa Hiroki, Komekado Hideyuki, Kita Ryuichi, Kimura Toru

doi:10.2957/kanzo.54.169

Bibliographic Information

Other Title

切除不能進行肝癌に対するsorafenib療法の初期投与量に関する検討～減量投与の意義と問題点について
セツジョフノウシンコウカンガンニタイスル sorafenib リョウホウノショキトウヨリョウニカンスルケントウゲンリョウトウヨノイギトモンダイテンニツイテ

Search this article

Abstract

Background: High rates of adverse effects and early discontinuation have been noted when using sorafenib to treat Japanese patients with unresectable hepatocellular carcinoma. The optimal initial dose of sorafenib is a matter of some debate.<br> Patients and Methods: We examined the relationship between the initial dose of sorafenib and the clinical course of 120 patients with hepatocellular carcinoma treated before September 2012.<br> Results: Those that took 400 mg (n=88) tended to have poorer performance status, but there was no significant difference in overall survival when compared with those who took 800 mg (n=32). In the 800 mg group, time to dose reduction or discontinuation of sorafenib was shorter than the 400 mg group. There was a positive relationship between duration of sorafenib administration and overall survival.<br> Conclusion: The duration of sorafenib administration appears to influence prognosis more than initial dose, which should be adjusted according to patient characteristics.<br>

Journal

Kanzo

Kanzo 54 (3), 169-177, 2013

The Japan Society of Hepatology

Keywords

Details 詳細情報について

Export